Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2024-03-21 Annual Report
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the 2023 annual report summary of Kunming Pharmaceutical Group Co., Ltd. It contains detailed financial data for the year 2023, including revenue, net profit, quarterly financial data, shareholder information, business overview, and strategic discussions. The document references the full annual report and includes audited financial statements with an unqualified audit opinion from KPMG Huazhen. The length is substantial (15,000 characters), and the content is comprehensive, covering company operations, financial performance, strategic initiatives, and governance. This matches the definition of an Annual Report (10-K) which is an official yearly report covering company activity and full financial performance. It is not merely an announcement or a summary but contains substantive financial data and analysis. Therefore, the correct classification is Annual Report (10-K) with high confidence. FY 2023
2024-03-21 Chinese
昆药集团2023年度环境、社会及管治（ESG）报告
Regulatory Filings
2024-03-21 Chinese
昆药集团2023年度内部控制审计报告
Regulatory Filings
2024-03-21 Chinese
昆药集团对2023年度会计师事务所履职情况的评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (毕马威华振) for the 2023 audit of 昆药集团股份有限公司. It details the qualifications, independence, quality control, and audit procedures of the auditor for the 2023 fiscal year. It does not contain the actual audited financial statements or the full annual report but rather an assessment of the auditor's performance and compliance with regulations. This type of document is a standalone audit-related report, not the full Annual Report (10-K) or the audit opinion itself. Therefore, it fits the category of Audit Report / Information (AR). The document length is 2342 characters, which is consistent with a detailed audit evaluation report rather than a brief announcement or certification. Hence, the classification is AR with high confidence. FY 2023
2024-03-21 Chinese
东海证券股份有限公司关于昆药集团股份有限公司2023年度募集资金存放与实际使用情况专项核查意见
Regulatory Filings
2024-03-21 Chinese
昆药集团股份有限公司董事会审计与风险控制委员会实施细则
Governance Information Classification · 95% confidence The document is titled as the 'Implementation Rules of the Board Audit and Risk Control Committee' of a company, detailing the committee's composition, responsibilities, decision-making procedures, and meeting rules. It references relevant laws and governance codes but does not contain financial statements, audit results, or report data. It is a governance-related internal regulation document rather than an audit report or financial report. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-03-04 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.